TRAPPC8 Human Pre-designed siRNA Set A

Cat. No.: T1478040

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Vue d’ensemble

TRAPPC8 Human Pre-designed siRNA Set A contains three designed siRNAs for TRAPPC8 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components TRAPPC8 siRNA-1: 5 nmol (HPLC) TRAPPC8 siRNA-2: 5 nmol (HPLC) TRAPPC8 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Conditions de stockage de stockage

Store at -20°C

Expédié en

Ice chest + Ice pads

Ce produit nécessite l'expédition en chaîne froide. Les services terrestres et autres services économiques ne sont pas disponibles.

Application Protocols

Only item-specific protocols from product data may be listed here.

• Tested/validated applications, recommended transfection reagents, siRNA working concentrations, and detailed stepwise procedures: Not specified for this item; refer to CoA/Spec Sheet.
• Positive controls, assay time points, and expected knockdown performance: Not specified for this item; refer to CoA/Spec Sheet.

Please see the Reaction & Applications and Reaction Conditions sections for general literature guidance, and consult the lot‑specific datasheet for definitive instructions.

Biological Roles

Target overview (literature)

• TRAPPC8 encodes a subunit of the Transport Protein Particle (TRAPP) complex, a conserved multi‑subunit tethering complex that regulates vesicle trafficking, notably ER‑to‑Golgi transport and Golgi maintenance. TRAPPC8 participates in the TRAPPII/III assemblies implicated in endosomal and autophagy‑related trafficking.

Cellular functions

• Vesicle tethering: Facilitates Rab GTPase activation and vesicle tethering to the Golgi apparatus as part of TRAPP; influences cargo sorting and membrane dynamics.
• Organelle integrity: Perturbation of TRAPPC8 can alter Golgi morphology and trafficking kinetics, impacting secretion and protein maturation pathways.
• Autophagy interface: TRAPPC8 has been associated with autophagosome formation/maturation pathways via TRAPP interactions (reported in the literature), making it a node for studying stress responses and proteostasis.

Use of this siRNA set

• By selectively reducing TRAPPC8 mRNA, researchers can interrogate its role in these pathways, evaluate compensatory mechanisms within TRAPP complexes, and perform epistasis mapping with other trafficking regulators (e.g., Rabs, SNAREs).

Notes

• Specific biological outcomes will depend on cell type, knockdown efficiency, and experimental conditions. This product is for research use only; no clinical or diagnostic use is implied.

Buffer Applications

Applicability

• As an siRNA reagent, this product is not used to prepare analytical buffers. Instead, buffers are relevant for reconstitution, storage, and transfection workflows.

General buffer guidance for siRNA (literature)

• Reconstitution: RNase‑free water or low‑salt Tris buffers (e.g., 10 mM Tris‑HCl, pH 7.5–8.0) are commonly used for preparing 10–100 µM stocks.
• Stabilizing buffer: TE (10 mM Tris‑HCl, 0.1–1 mM EDTA, pH 7.5–8.0) can improve long‑term stability by chelating divalent cations that catalyze hydrolysis; verify EDTA compatibility with your transfection method.
• Working dilutions: Prepare in serum‑free, antibiotic‑free transfection medium immediately before delivery; replace with complete medium after complex formation/uptake per transfection reagent guidance.
• RNase control: Use certified RNase‑free solutions and consumables; avoid buffers containing RNases or Mg2+/Ca2+ unless required.

Item-specific details

• Buffer composition, concentration, and recommended reconstitution volume are not specified for this item; refer to the CoA/Spec Sheet.

Green Alternatives

Relevance

• This product is a biological oligonucleotide reagent used in cell‑based experiments rather than a volatile organic solvent or bulk chemical. Traditional “green solvent” substitution frameworks are not directly applicable.

General sustainability considerations (literature)

• Alternatives to genetic manipulation: Transient siRNA knockdown can reduce resource‑intensive stable cell line generation compared with CRISPR editing when short‑term phenotyping suffices.
• Resource efficiency: Use pooled siRNAs to minimize repeat transfections and reduce plastic consumables; plan experiments to optimize well usage and reagent volumes.
• Waste minimization: Prepare concentrated stocks and aliquot to extend shelf life and decrease discarded, degraded solutions; dispose of aqueous nucleic acid waste via standard non‑hazardous streams where allowed.

Packaging and cold chain

• Product ships on cold packs; consolidate orders and coordinate deliveries to reduce shipping frequency and associated environmental impact.

Note

• There are no item‑specific “greener formulation” details available; operational choices in experimental design primarily drive sustainability for siRNA use.

Pharmaceutical Uses

This catalog item is for research use only.

• No pharmacopeial monograph, excipient role, or GMP manufacturing use is specified for this item; refer to CoA/Spec Sheet for any regulatory or quality statements that may accompany a specific lot.
• siRNA materials like this are commonly employed in discovery research and preclinical laboratory studies to interrogate gene function. They are not intended for human or veterinary therapeutic, diagnostic, or clinical applications.

Physical Properties

Item-specific specs

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Extinction coefficient, MW, purity: Not specified for this item; refer to CoA/Spec Sheet.

General/literature properties of siRNA (sequence‑dependent)

• Physical state: Dry (lyophilized) solid or aqueous solution, depending on format; hygroscopic; non‑volatile.
• Solubility: Freely soluble in RNase‑free water and low‑ionic‑strength buffers (e.g., 10 mM Tris‑HCl, pH 7.0–8.0) to concentrations typically 10–100 µM; higher concentrations possible depending on length and modifications.
• UV absorbance: Strongly absorbing at 260 nm (A260) with sequence‑dependent ε; base composition dictates exact values.
• pKa/logP: Not typically defined for polyanionic oligonucleotides; behavior dominated by phosphate backbone charge.
• Stability (general): Stable at −20 °C when dry; in solution, stable at −20 °C for months; avoid repeated freeze–thaw cycles; RNase contamination rapidly degrades RNA.
• Incompatibilities: Degraded by RNases; adsorption losses on untreated plastics at sub‑nanomolar concentrations.

Important

• Any specific numerical values (e.g., concentration, extinction coefficient) are sequence‑ and lot‑dependent and are not specified for this item; consult the CoA/Spec Sheet.

Quality and Grades

Item-specific quality information

• Grade/purity: Not specified for this item; refer to CoA/Spec Sheet.
• Stabilizers/modifications: Not specified for this item; refer to CoA/Spec Sheet.

Context for siRNA quality (general/literature)

• Typical siRNA purities: Desalted (crude), cartridge‑purified, or HPLC‑purified; HPLC purification is commonly used to minimize n‑1/n+1 species and truncated strands for sensitive applications.
• Identity/quality controls: Vendors often provide analytical RP‑HPLC traces and/or mass spectrometry (MALDI‑TOF/ESI) confirmation; strand stoichiometry and annealing efficiency may be specified for duplexes.
• UV and concentration: siRNA concentration is typically reported by A260 using a lot‑specific extinction coefficient; exact values are sequence‑dependent.
• Endotoxin/bioburden: For cell‑based assays, low endotoxin levels are preferred; acceptance criteria vary and are item‑specific.
• RNase‑free assurance: Manufacturing in RNase‑controlled environments reduces risk of degradation; certificates may indicate RNase/DNase‑free status.

How to use this information

• In the absence of item‑specific specs above, consult the CoA/Spec Sheet for this catalog number for: purification grade, quantitation method, sequence disclosure (if provided), residual solvent/salt profile, and recommended use level.

Reaction and Applications

Item-specific application context

• Product is a pre‑designed siRNA set targeting human TRAPPC8 for RNA interference experiments in research settings.

General applications (literature)

• Gene silencing: Sequence‑specific knockdown of TRAPPC8 mRNA in mammalian cell lines to interrogate vesicular trafficking pathways and TRAPP complex biology.
• Pathway analysis: Dissect roles of TRAPPC8 in ER‑to‑Golgi transport, autophagy‑related trafficking, and Golgi organization by transient loss‑of‑function.
• Synthetic lethality/epistasis: Combine TRAPPC8 knockdown with chemical probes or additional siRNAs to map genetic interactions.
• Assay readouts: qRT‑PCR and RNA‑seq for mRNA knockdown; immunoblotting or targeted proteomics for protein reduction; imaging of trafficking markers (e.g., ER‑Golgi transport assays) for phenotypic endpoints.
• Controls: Use non‑targeting siRNA, positive knockdown controls (e.g., PLK1 for transfection benchmarking), and siRNA‑resistant rescue constructs to establish specificity.

Practical tips (general)

• Use pooled designs: Combining multiple TRAPPC8 siRNAs can improve knockdown magnitude and mitigate off‑target effects.
• Dose/time optimization: Titrate 1–50 nM siRNA and sample at 24–96 h post‑transfection, aligning with target protein half‑life.
• Delivery: Select lipid, polymer, or electroporation methods appropriate for the cell type; validate with a fluorescent siRNA uptake control.

Note

• No item‑specific sequences, concentrations, or efficacy metrics are provided here; consult the CoA/Spec Sheet for this item.

Reaction Conditions

Note: There are no item‑specific transfection or assay conditions provided for this product. The following are general literature guidelines for siRNA knockdown experiments; optimize empirically for your system.

General transfection parameters (literature)

• Cell density: Plate adherent cells at 30–60% confluence for transfection; aim for 70–90% at assay time.
• siRNA dose: 1–50 nM final concentration; start with 5–10 nM for lipid‑mediated delivery; adjust based on toxicity and knockdown.
• Complexation: Prepare siRNA–reagent complexes in serum‑free medium (e.g., Opti‑MEM) for 5–20 min per reagent instructions.
• Incubation: Expose cells to complexes for 4–24 h; then replace with complete medium. Some reagents support no‑change protocols.
• Timing: Assess mRNA reduction at 24–48 h; protein knockdown often peaks at 48–96 h depending on protein half‑life.
• Controls: Non‑targeting siRNA, positive knockdown control, and mock transfection; include a fluorescent siRNA to monitor uptake if needed.
• Readouts: qRT‑PCR (ΔΔCt), Western blotting, flow cytometry, or imaging; normalize to housekeeping genes/proteins validated for stability under your conditions.

Environmental considerations

• Maintain RNase‑free technique; avoid repeated freeze–thaw of siRNA stocks by aliquoting on first thaw.

Reminder

• For any lot‑specific recommendations, consult the CoA/Spec Sheet.

Safety and Handling

Item-specific hazard data

• GHS classification, signal word, pictograms, H‑statements: Not specified for this item; refer to the product SDS for authoritative information.

General laboratory safety for synthetic siRNA

• Expected hazards: Synthetic oligonucleotides are generally considered low acute toxicity and non‑volatile; however, handle as a laboratory chemical. Avoid inhalation of dust/aerosols and contact with skin/eyes.
• PPE: Lab coat, safety glasses, and disposable nitrile gloves. Change gloves frequently during RNase‑free work.
• RNase control: Use RNase‑free tips/tubes and dedicated reagents; decontaminate work surfaces and equipment with RNase deactivation solutions; avoid touching tube rims and caps.
• First aid (general): If inhaled—move to fresh air. Skin contact—wash with soap and water. Eye contact—rinse cautiously with water for several minutes; remove contact lenses if easy. Ingestion—rinse mouth and seek medical attention if unwell. Always follow institutional procedures.
• Storage incompatibilities: Keep separate from RNase sources (biological samples, non‑dedicated gloves), strong oxidants, and nucleases. Avoid prolonged exposure to elevated temperature and moisture.
• Waste: Dispose of aqueous nucleic acid solutions and contaminated consumables per local regulations for non‑hazardous laboratory biological/chemical waste.

Note

• Always consult the product’s SDS and your institution’s EHS guidelines for definitive hazard classifications and handling requirements.

Solvent Selection

Applicability to siRNA

• siRNA is reconstituted in aqueous, RNase‑free media. Organic solvents are generally contraindicated due to denaturation and poor solubility of polyanionic oligonucleotides.

Recommended media (general/literature)

• RNase‑free water: Common for short‑term use and stock preparation.
• TE buffer (RNase‑free): 10 mM Tris‑HCl, 0.1–1 mM EDTA, pH 7.5–8.0; EDTA chelates divalent cations that can catalyze hydrolysis; suitable for long‑term storage of aliquots.
• PBS without divalent cations: Acceptable for working solutions; avoid Mg2+/Ca2+ unless required for downstream applications.
• Avoid: Alcohols, chlorinated solvents, and high concentrations of chaotropes unless specifically required for formulation; these can precipitate or destabilize duplex RNA.

Practical considerations

• Concentration targets: Prepare 10–100 µM stocks to minimize adsorption losses; dilute into serum‑free transfection medium immediately before use.
• Containers: Use low‑bind, RNase‑free plastics; pre‑wet tips with solution to reduce surface loss at low nM levels.

Comparison (general)

• Water vs TE: Water is simplest and compatible with most transfection reagents; TE offers enhanced stability during storage due to EDTA, but confirm EDTA compatibility with your transfection chemistry.

Storage and Reconstitution

Item-specific instructions (from Product Data)

• Storage: Store at −20 °C.
• Shipping: Shipped in ice chest with ice pads.

Additional details

• Reconstitution solvent, target concentration, and buffer composition: Not specified for this item; refer to CoA/Spec Sheet.
• Working aliquots, freeze–thaw guidance, and shelf life: Not specified for this item; refer to CoA/Spec Sheet.

General notes (for planning only; verify against datasheet)

• Upon receipt, keep product cold; minimize exposure to ambient temperatures. If lyophilized, allow the vial to equilibrate to room temperature in a desiccator before opening to prevent condensation. Prepare RNase‑free aliquots on first use and return remaining material to −20 °C promptly.

Structure and Identity

Item-specific facts (from Product Data)

• Product: TRAPPC8 Human Pre-designed siRNA Set A (SKU: T1478040)
• Intended target: human TRAPPC8 mRNA (Trafficking Protein Particle Complex subunit 8)
• Molecular formula: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight: Not specified for this item; refer to CoA/Spec Sheet.
• SMILES / InChIKey: Not applicable to siRNA mixtures; not specified for this item.

General description (literature)

• Composition: A set of synthetic small interfering RNAs (siRNAs), typically double‑stranded ~21–23 nt RNAs with 2‑nt 3′ overhangs designed to mediate RNA interference (RNAi) against TRAPPC8 transcripts.
• Structural features: Each duplex contains a sense and antisense strand with phosphodiester or modified backbones; exact sequences and modifications are sequence‑dependent and not provided here.
• 2D/functional depiction in words: Two antiparallel RNA strands forming a short A‑form helix; the antisense (guide) strand is incorporated into RISC to direct sequence‑specific cleavage/silencing of complementary TRAPPC8 mRNA.

Notes

• As this is a set, it commonly comprises multiple non‑overlapping siRNA duplexes targeting distinct regions of the TRAPPC8 transcript to improve knockdown robustness; exact count and sequences are not specified for this item.

Synthetic Utility

Not typically applicable.

• As an siRNA set, this product is a biological reagent for gene silencing and is not used as a building block, catalyst, or solvent in chemical synthesis.

Related general information (literature)

• Chemical modification strategies (e.g., 2′‑O‑Me, 2′‑F, phosphorothioate linkages) can tune stability and potency of siRNAs, but any such modifications for this item are not specified; refer to CoA/Spec Sheet if applicable.

Target Specificity

Item-specific details

• Target: Human TRAPPC8 mRNA (Trafficking Protein Particle Complex subunit 8).
• Format: Pre‑designed siRNA Set A (multiple duplexes targeting TRAPPC8; exact count, sequences, and target regions are not specified for this item).
• Species reactivity: Human (as indicated by product name); cross‑reactivity with other species is not specified for this item.
• Off‑target assessment, algorithm, and in silico specificity metrics: Not specified for this item; refer to CoA/Spec Sheet.

Notes

• For validation, end users should confirm target knockdown by qRT‑PCR and/or immunodetection of TRAPPC8 protein in their specific cell model.